Objective
to report the 5 years clinical outcomes of zotarolimus-eluting (Resolute Integrity) as compared to Everolimus-eluting (Promus Element) coronary stenting in all-comers
Study
multicentre, patient-blinded randomised trial
Population
all-comers giving informed consent
Endpoints
TVF as a composite of cardiac death, target-vessel MI or clinically-indicated TVR at 5 years
Conclusion
at 5 years there were no significant differences of adverse clinical events between stenting with zotarolimus-eluting as compared to everolimus-eluting stents used in all-comers
Zocca et al. J Am Coll Cardiol Interv. 2018;11:462-9